Evaluation of the anti-human agonist GITR antibody MK-4166 (Figure 2C) in a humanized mouse cancer model has mirrored many effects observed in syngeneic mouse tumor models, including a reduction in Treg numbers and suppressive phenotype, alongside enhanced effector responsiveness [123]. Here, TNFRSF18 is linked to neoplasm.